Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

ZURAMPIC Drug Profile

« Back to Dashboard

Which patents cover Zurampic, and what substitute generic drugs are available?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and fifty-four patent family members in thirty-eight countries.

The generic ingredient in ZURAMPIC is lesinurad. One supplier is listed for this compound. Additional details are available on the lesinurad profile page.

Summary for Tradename: ZURAMPIC

Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list24
Patent Applications: see list42
Drug Prices:see details
DailyMed Link:ZURAMPIC at DailyMed

Pharmacology for Tradename: ZURAMPIC

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes8,283,369► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes8,546,437► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes8,357,713► SubscribeY ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes9,216,179► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes8,084,483► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZURAMPIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,946,273S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase► Subscribe
7,435,752N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors► Subscribe
8,252,828S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,481,581S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,344,012Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZURAMPIC

Country Document Number Estimated Expiration
Canada2802407► Subscribe
Hong Kong1172326► Subscribe
India3762CHN2014► Subscribe
Japan2014196373► Subscribe
South Korea20130105902► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZURAMPIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
169Luxembourg► SubscribePRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
0825Netherlands► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
2016024Lithuania► SubscribePRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc